Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

Transplantation

Volumn 71, Issue 9, 2001, Pages 1282-1287

  Vincenti, F ^a   Ramos, E ^b   Brattstrom, C ^c   Cho, S ^d   Ekberg, H ^e   Grinyo, J ^f   Johnson, R ^g   Kuypers, D ^h   Stuart, F ⁱ   Khanna, A ^j   Navarro, M ^b   Nashan, B ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Roche Global Development   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d BOSTON MEDICAL CENTER   (United States)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; OKT 3;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; STEROID THERAPY; SURVIVAL;

EID: 0035872742     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200105150-00017     Document Type: Article

References (16)

1. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine
2. Reduction of acute renal allograft rejection by daclizumab
3. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
4. A phase I trial of humanized anti-interleukin 2 receptor in renal transplantation
5. Intra-renal expression of fibro-genic genes in renal allografts with tacrolimus and cyclosporine nephrotoxicity
6. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
7. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection
8. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporin and FK 506
9. Nephrotoxic effects of primary immunosuppression with FK 506 and cyclosporin regimens after liver transplantation
10. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK 506. Clinical significance and comparison with cyclosporine
11. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 Year pooled analysis
12. The intragraft gene activation of markers reflecting T-cell-activation and-cytotoxicity analyzed by quantitative RT-PCR in renal transplantation
13. Organ specific T-cell growth factor and CTL gene activation in renal and liver transplant rejection
14. Interleukin-15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells
15. Sparing of calcineurin antagonists: The use of interleukin-2 monoclonal antibodies in conjunction with mycophenolate mofetil
16. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection